614 related articles for article (PubMed ID: 27170757)
1. HIV-1 Vpu Antagonizes CD317/Tetherin by Adaptor Protein-1-Mediated Exclusion from Virus Assembly Sites.
Pujol FM; Laketa V; Schmidt F; Mukenhirn M; Müller B; Boulant S; Grimm D; Keppler OT; Fackler OT
J Virol; 2016 Aug; 90(15):6709-6723. PubMed ID: 27170757
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 Vpu blocks recycling and biosynthetic transport of the intrinsic immunity factor CD317/tetherin to overcome the virion release restriction.
Schmidt S; Fritz JV; Bitzegeio J; Fackler OT; Keppler OT
mBio; 2011; 2(3):e00036-11. PubMed ID: 21610122
[TBL] [Abstract][Full Text] [Related]
3. A cytoplasmic tail determinant in HIV-1 Vpu mediates targeting of tetherin for endosomal degradation and counteracts interferon-induced restriction.
Kueck T; Neil SJ
PLoS Pathog; 2012; 8(3):e1002609. PubMed ID: 22479182
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 Vpu's lipid raft association is dispensable for counteraction of the particle release restriction imposed by CD317/Tetherin.
Fritz JV; Tibroni N; Keppler OT; Fackler OT
Virology; 2012 Mar; 424(1):33-44. PubMed ID: 22222210
[TBL] [Abstract][Full Text] [Related]
5. β-TrCP is dispensable for Vpu's ability to overcome the CD317/Tetherin-imposed restriction to HIV-1 release.
Tervo HM; Homann S; Ambiel I; Fritz JV; Fackler OT; Keppler OT
Retrovirology; 2011 Feb; 8():9. PubMed ID: 21310048
[TBL] [Abstract][Full Text] [Related]
6. Vpu binds directly to tetherin and displaces it from nascent virions.
McNatt MW; Zang T; Bieniasz PD
PLoS Pathog; 2013; 9(4):e1003299. PubMed ID: 23633949
[TBL] [Abstract][Full Text] [Related]
7. The C-Terminal End of HIV-1 Vpu Has a Clade-Specific Determinant That Antagonizes BST-2 and Facilitates Virion Release.
Sharma S; Jafari M; Bangar A; William K; Guatelli J; Lewinski MK
J Virol; 2019 Jun; 93(11):. PubMed ID: 30867310
[TBL] [Abstract][Full Text] [Related]
8. Contribution of the Cytoplasmic Determinants of Vpu to the Expansion of Virus-Containing Compartments in HIV-1-Infected Macrophages.
Leymarie O; Lepont L; Versapuech M; Judith D; Abelanet S; Janvier K; Berlioz-Torrent C
J Virol; 2019 Jun; 93(11):. PubMed ID: 30867316
[TBL] [Abstract][Full Text] [Related]
9. Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein.
Vigan R; Neil SJ
J Virol; 2010 Dec; 84(24):12958-70. PubMed ID: 20926557
[TBL] [Abstract][Full Text] [Related]
10. Antagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment.
Dubé M; Roy BB; Guiot-Guillain P; Binette J; Mercier J; Chiasson A; Cohen EA
PLoS Pathog; 2010 Apr; 6(4):e1000856. PubMed ID: 20386718
[TBL] [Abstract][Full Text] [Related]
11. Expression of HIV-1 Vpu leads to loss of the viral restriction factor CD317/Tetherin from lipid rafts and its enhanced lysosomal degradation.
Rollason R; Dunstan K; Billcliff PG; Bishop P; Gleeson P; Wise H; Digard P; Banting G
PLoS One; 2013; 8(9):e75680. PubMed ID: 24086611
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of inactive tetherin delGPI mutant inhibits HIV-1 Vpu-mediated antagonism of endogenous tetherin.
Lv M; Wang J; Zhu Y; Wang X; Zuo T; Liu D; Zhang J; Wu J; Zhang H; Kong W; Yu X
FEBS Lett; 2013 Jan; 587(1):37-43. PubMed ID: 23201263
[TBL] [Abstract][Full Text] [Related]
13. Structural basis of HIV-1 Vpu-mediated BST2 antagonism via hijacking of the clathrin adaptor protein complex 1.
Jia X; Weber E; Tokarev A; Lewinski M; Rizk M; Suarez M; Guatelli J; Xiong Y
Elife; 2014 Apr; 3():e02362. PubMed ID: 24843023
[TBL] [Abstract][Full Text] [Related]
14. Antagonism of CD317 restriction of human immunodeficiency virus type 1 (HIV-1) particle release and depletion of CD317 are separable activities of HIV-1 Vpu.
Goffinet C; Homann S; Ambiel I; Tibroni N; Rupp D; Keppler OT; Fackler OT
J Virol; 2010 Apr; 84(8):4089-94. PubMed ID: 20147395
[TBL] [Abstract][Full Text] [Related]
15. Serine Phosphorylation of HIV-1 Vpu and Its Binding to Tetherin Regulates Interaction with Clathrin Adaptors.
Kueck T; Foster TL; Weinelt J; Sumner JC; Pickering S; Neil SJ
PLoS Pathog; 2015 Aug; 11(8):e1005141. PubMed ID: 26317613
[TBL] [Abstract][Full Text] [Related]
16. Vpu of a Simian Immunodeficiency Virus Isolated from Greater Spot-Nosed Monkey Antagonizes Human BST-2 via Two AxxxxxxxW Motifs.
Yao W; Yoshida T; Hashimoto S; Takeuchi H; Strebel K; Yamaoka S
J Virol; 2020 Jan; 94(2):. PubMed ID: 31666374
[TBL] [Abstract][Full Text] [Related]
17. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism.
Douglas JL; Viswanathan K; McCarroll MN; Gustin JK; Früh K; Moses AV
J Virol; 2009 Aug; 83(16):7931-47. PubMed ID: 19515779
[TBL] [Abstract][Full Text] [Related]
18. HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation.
Mangeat B; Gers-Huber G; Lehmann M; Zufferey M; Luban J; Piguet V
PLoS Pathog; 2009 Sep; 5(9):e1000574. PubMed ID: 19730691
[TBL] [Abstract][Full Text] [Related]
19. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu.
Neil SJ; Zang T; Bieniasz PD
Nature; 2008 Jan; 451(7177):425-30. PubMed ID: 18200009
[TBL] [Abstract][Full Text] [Related]
20. Cell-cell spread of human immunodeficiency virus type 1 overcomes tetherin/BST-2-mediated restriction in T cells.
Jolly C; Booth NJ; Neil SJ
J Virol; 2010 Dec; 84(23):12185-99. PubMed ID: 20861257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
